ライフサイエンスコーパス: doxazosin

1 HFPEF and HFREF compared with amlodipine and doxazosin.

2 dhesion response of prostate cancer cells to doxazosin.

3 azoline-based alpha1-adrenoceptor antagonist doxazosin.

4 <0.001) and finasteride (P<0.001) but not by doxazosin.

5 idone as the first-line drug was superior to doxazosin.

6 Chlorthalidone (12.5 to 25 mg/d) or doxazosin (2 to 8 mg/d) for a planned follow-up of 4 to

7 in PC-3 and BPH-1 cells after treatment with doxazosin (25 micromol/L, 6 and 24 hours) to identify th

8 d, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 230 patients

9 After the addition of doxazosin, 29.7% of participants achieved target BP.

10 ne (-3.8 mm Hg), lisinopril (-2.4 mm Hg), or doxazosin (-3.8 mm Hg).

11 ract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finas

12 ents randomized to receive 3-5 weeks of oral doxazosin 4 mg daily or placebo in crossover fashion.

13 pared with the individual treatments; versus doxazosin (-4.03 [-5.04 to -3.02]; p<0.0001) and versus

14 Doxazosin (50 nmol), an alpha(1)-adrenergic antagonist,

15 ypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of alpha1-adrenore

16 an in vivo efficacy trial demonstrated that doxazosin administration (at tolerated pharmacologically

17 oline-derived alpha1-adrenoceptor antagonist doxazosin affects the attachment and migration of prosta

18 ural optimization of the chemical nucleus of doxazosin and a subsequent structure-function analysis t

19 sterol and LDL cholesterol were greater with doxazosin and acebutolol (for plasma total cholesterol,

20 maspin cells exhibited higher sensitivity to doxazosin and an earlier temporal activation of caspase-

21 the mean of the other two active treatments (doxazosin and bisoprolol; -4.26 [-5.13 to -3.38]; p<0.00

22 e development of antiangiogenic targeting by doxazosin and derivative agents for advanced prostate ca

23 Decreases in triglycerides were greater with doxazosin and enalapril, least with acebutolol.

24 Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk

25 istically significant declines in the use of doxazosin and other alpha-blockers coincided with the ea

26 There was a significant difference between doxazosin and placebo for nasal blockage score and heart

27 Alfuzosin, terazosin, doxazosin and silodosin have all been shown to be effect

28 his apoptosis induction, we examined whether doxazosin and terazosin (both piperazinyl quinazolines)

29 These findings demonstrate the ability of doxazosin and terazosin (but not tamsulosin) to suppress

30 This suggests that the apoptotic activity of doxazosin and terazosin against prostate cells is indepe

31 ased alpha1-adrenoceptor antagonists such as doxazosin and terazosin have been previously shown to in

32 strated that alpha1-adrenoceptor antagonists doxazosin and terazosin induced apoptosis in prostate ep

33 oline-based alpha1-adrenoceptor antagonists (doxazosin and terazosin) against prostate cancer cells i

34 oline-based alpha1-adrenoceptor antagonists, doxazosin and terazosin, exhibit a potent apoptotic effe

35 tic (chlorthalidone), (5) alpha1-antagonist (doxazosin), and (6) angiotensin-converting enzyme inhibi

36 re, until ironclad safety data are provided, doxazosin, and probably all alpha-blockers, should no lo

37 ng the diagnosis and mortality of CHF in the doxazosin arm and regarding the risk of dying from malig

38 ded with the early termination of the ALLHAT doxazosin arm.

39 e the identification and characterization of doxazosin as a novel small molecule agonist for EphA2 an

40 ers metoprolol (beta1-selective), metoprolol+doxazosin (beta1/alpha1), or carvedilol (beta1/beta2/alp

41 Trial reported that treatment initiated with doxazosin compared with chlorthalidone doubled the risk

42 e higher risk for heart failure while taking doxazosin compared with chlorthalidone is attenuated but

43 low sensitivity to the apoptotic effects of doxazosin compared with that observed for the malignant

44 w-up, 1.74 years); and in the chlorthalidone/doxazosin comparison that was terminated early, 20.0% of

45 Smaller doses (5 or 25 nmol) of doxazosin did not alter bladder activity.

46 ed in 641 participants (2.0%) and, excluding doxazosin, did not differ by antihypertensive treatment

47 These results show that doxazosin exerts its apoptotic effects against benign an

48 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measu

49 between single and chronic dosing effects of doxazosin for nasal symptoms, oxymetazoline response and

50 pressure (BP) and biochemical parameters of doxazosin GITS (gastrointestinal therapeutic system) as

51 in the first 6 to 12 hours of treatment with doxazosin in both PC-3 and BPH-1 cells.

52 as the underlying mechanism of the effect of doxazosin in prostate cells.

53 ne-based) compounds with higher potency than doxazosin in suppressing prostate growth by targeting ti

54 The role of doxazosin in treatment of hypertension remains controver

55 Under isovolumetric conditions this dose of doxazosin increased bladder contraction frequency and de

56 Doxazosin increased FADD recruitment and subsequent casp

57 Doxazosin-induced apoptosis was blocked by specific casp

58 g the functional involvement of caspase-8 in doxazosin-induced apoptosis.

59 Moreover, EM2 reduced agonist doxazosin-induced EphA2 phosphorylation and cells roundi

60 The alpha1-adrenoreceptor antagonist doxazosin induces apoptosis in malignant cells with mode

61 Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an

62 ontrolled, the present findings suggest that doxazosin is a safe and effective third-line antihyperte

63 To our knowledge, doxazosin is the first small molecule agonist of a recep

64 cholesterol were greater with enalapril and doxazosin, least with acebutolol.

65 Among those who received doxazosin, mean age was 63 years (SD 9 years), 79% were

66 blunted after single vs chronic dosing with doxazosin: mean difference -17 L/min (95% CI -30 to -4)

67 ow (PNIF) between baseline vs. first dose of doxazosin: mean difference -19 L/min (95% CI -35 to -2)

68 ere worse between baseline vs. first dose of doxazosin: mean difference VAS -10 mm (95% CI -18 to -2)

69 esis that the alpha-receptor inverse agonist doxazosin might produce beneficial effects in allergic r

70 onolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin modified release (4-8 mg), and placebo, in add

71 (lisinopril; n = 8233), or an alpha-blocker (doxazosin; n = 8195).

72 Neither doxazosin nor terazosin exerted a significant effect on

73 The separation of the effect of doxazosin on apoptosis from its original pharmacological

74 The effect of doxazosin on cell attachment of maspin-expressing prosta

75 The effect of doxazosin on recruitment of Fas-associated death domain

76 all were significantly inhibited with daily doxazosin or apocynin (inhibitors of alpha1-AR and NADPH

77 s, does not abrogate the apoptotic effect of doxazosin or terazosin against human prostate cancer or

78 that treatment of prostate cancer cells with doxazosin or terazosin results in a significant loss of

79 nificantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone.

80 Doxazosin (P<0.001), finasteride (P=0.001), and combinat

81 h combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone.

82 o chlorthalidone, amlodipine, lisinopril, or doxazosin, providing an opportunity to compare these tre

83 Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate ca

84 Doxazosin resulted in dramatic downregulation of the 189

85 reatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin and silodosin.

86 by boceprevir led to increased exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in a

87 on of three alpha1-adrenoceptor antagonists, doxazosin, terazosin, and tamsulosin, against prostate c

88 own the risk of CHF to be twice as high with doxazosin than with chlorthalidone.

89 PEF compared with amlodipine, lisinopril, or doxazosin; the hazard ratios were 0.69 (95% confidence i

90 he risk of HFREF compared with amlodipine or doxazosin; the hazard ratios were 0.74 (95% CI, 0.59 to

91 Patients assigned to doxazosin therapy had a mean in-trial systolic/diastolic

92 Here, we demonstrate that the ability of doxazosin to induce apoptosis in PC-3 prostate cancer ce

93 ine-based alpha(1)-adrenoreceptor antagonist doxazosin to suppress prostate tumor growth via apoptosi

94 ability to attach to ECM-coated plates, and doxazosin treatment considerably antagonized this effect

95 rtile range 4 to 31 months) of uninterrupted doxazosin treatment, during which other antihypertensive

96 Excluding doxazosin, treatment assignment to either antihypertensi

97 o chlorthalidone, amlodipine, lisinopril, or doxazosin treatments and followed up for 4 to 8 years.

98 Treatment with doxazosin triggered EphA2 receptor internalization, and

99 as no apparent excess of heart failure among doxazosin users.

100 py, the relative risk for heart failure with doxazosin versus chlorthalidone was 3.10 (CI, 2.51 to 3.

101 major cardiovascular events associated with doxazosin was attributed primarily to a doubling in the

102 nes of human prostate cancer cells DU-145 to doxazosin was evaluated by determining cell viability, a

103 Doxazosin was generally well tolerated, with 7.5% of par

104 Doxazosin was initiated a median of 8 months (interquart

105 at treatment with amlodipine, lisinopril, or doxazosin was not superior to thiazide-like diuretic (ch

106 r of apoptotic cells detected in response to doxazosin was significantly higher compared to the neo c

107 g followed by addition of bendrofluazide and doxazosin whenever needed.

108 ihydro-benzo[1,4]dioxane)-carbonyl moiety of doxazosin with aryl-sulfonyl functions dramatically impr

109 NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic